repaglinide / Generic mfg. - LARVOL DELTA

Pharmacokinetic Effect of Y-3 on Repaglinide，Warfarin and Omeprazole in Healthy Participants (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Neurodawn Pharmaceutical Co., Ltd. | Recruiting ➔ Completed

Trial completion

To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: SpringWorks Therapeutics, Inc.

New P1 trial

Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=28 | Recruiting | Sponsor: Institut de Recherches Internationales Servier (I.R.I.S.)

New P1 trial • Breast Cancer • Oncology • Solid Tumor

Effect of Oral Hypoglycaemic Agents on Carotid Artery Intima-Media Thickness in Patients With Cardiovascular Disease and/or Diabetes-A Systematic Review. (PubMed, Endocrinol Diabetes Metab) - "The study suggests that prolonged use of Pioglitazone, Repaglinide and Alogliptin may significantly slow CIMT progression, improving cardiovascular risk management in patients with diabetes and/or cardiovascular disease. Further research is needed to understand the benefits and optimise oral hypoglycaemic treatment strategies for these patients."

Journal • Review • Atherosclerosis • Cardiovascular • Diabetes • Hypoglycemia • Inflammation • Metabolic Disorders • Type 1 Diabetes Mellitus

Noninsulin drugs for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Chitosan-based hydrogels loaded with repaglinide and difluorinated curcumin: impact on structural integrity, drug release, and antibacterial activity. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "The co-loading of Ripa and dfCur into a thermoresponsive chitosan hydrogel produced a synergistic platform with enhanced biocompatibility, potent antibacterial effects, and controlled drug release. This multifunctional dressing shows promise for advanced DFU management and warrants further in vivo evaluation."

Journal • Infectious Disease

LC-MS/MS-based investigation of pharmacokinetic interactions between CYP3A4 substrates enzalutamide and repaglinide in rats. (PubMed, Anal Methods) - "Co-administration of these drugs in rats allowed assessment of the potential DDI. We report that ENZ, as a CYP3A4 inducer, alters the REP pharmacokinetic parameters, and clinicians must consider this before prescribing them."

Journal • PK/PD data • Preclinical • Castration-Resistant Prostate Cancer • Diabetes • Genito-urinary Cancer • Metabolic Disorders • Oncology • Prostate Cancer • Solid Tumor • Type 2 Diabetes Mellitus • CYP3A4

Human cytochrome P4502C8 metabolizes repaglinide to 4'-hydroxyrepaglinide, not 3'-hydroxyrepaglinide. (PubMed, Drug Metab Dispos) - "This transformation has been used as a marker for CYP2C8 in clinical and in vitro studies. These data unequivocally demonstrate that the absolute structure of the hydroxyrepaglinide metabolite generated by CYP2C8 is 4'-hydroxymetabolite, not 3'-hydroxyrepaglinide as previously claimed."

Journal • CYP2C8

A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants (clinicaltrials.gov) - P1 | N=49 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed

Trial completion

Dietary Modulation of CYP3A4 and Its Impact on Statins and Antidiabetic Drugs: A Narrative Review. (PubMed, Pharmaceuticals (Basel)) - "Specific examples include simvastatin, atorvastatin, repaglinide, and saxagliptin, whose systemic exposure can be significantly altered by dietary factors. Clinicians should remain aware of potential CYP3A4-related food-drug interactions and consider dietary habits and supplement use in therapeutic decision-making. Future research should aim to integrate pharmacogenomics, gut microbiome profiling, and personalized nutrition in order to improve the prediction and prevention of clinically significant interactions."

Journal • Review • CYP3A4

Acarbose-Induced Pneumatosis Cystoides Intestinalis. (PubMed, JCEM Case Rep) - "His blood glucose levels were subsequently managed with repaglinide. This report further underscores the critical need for increased awareness of PCI in patients receiving α-glucosidase inhibitors and emphasizes the broader importance of pharmacovigilance in identifying rare adverse drug reactions. Further research is warranted to elucidate the precise causal relationship and to explore potential preventive strategies."

Journal • Diabetes • Infectious Disease • Metabolic Disorders • Pain • Type 2 Diabetes Mellitus

Partial non-adherence to antidiabetic therapy worsens diabetes management and correlates with treatment complexity: a comprehensive study using direct blood analysis (EASD 2025) - "In addition, patients completed a questionnaire assessing lifestyle factors and medication-taking habits. Adherence to metformin was very high, with the drug undetected in only 2.4% of patients. In contrast, adherence rates were lower for other medications—94% for sulfonylurea analogs, 90% for DPP-4 inhibitors, and 82% for pioglitazone—with the lowest rates observed for SGLT2 inhibitors (73%) and repaglinide (fewer than 50%)... Partial non-adherence is common in T2D and is closely linked to treatment complexity and poor glycemic outcomes. These findings highlight the need for patient-specific strategies to improve adherence and optimize long-term diabetes management."

Adherence • Diabetes • Diabetic Neuropathy • Metabolic Disorders • Type 2 Diabetes Mellitus

Emerging nanotechnology-based therapies in the treatment of diabetes: recent developments and future opinion. (PubMed, Drug Dev Ind Pharm) - "Glipizide sustained-release nanoparticles, repaglinide-loaded polymeric systems, and metformin-loaded alginate nanocapsules are just a few of the nanoformulations that have shown markedly improved pharmacokinetics and therapeutic efficacy in preclinical models. The development of new nano formulations shows great promise in preventing hyperglycaemia and improving diabetes management; however, challenges such as biocompatibility, scalability, and regulatory approval pose substantial obstacles to clinical implementation. Nevertheless, the expanding roles of nanotechnology in diabetes therapy present transformative opportunities, highlighting the necessity for ongoing interdisciplinary research to refine these nanotherapeutics for safe and effective clinical applications."

Journal • Review • Diabetes • Metabolic Disorders

A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants (clinicaltrials.gov) - P1 | N=49 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed

Pharmacokinetic Effect of Y-3 on Repaglinide，Warfarin and Omeprazole in Healthy Participants (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Neurodawn Pharmaceutical Co., Ltd.

New P1 trial

A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Vincentage Pharma Co., Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Vincentage Pharma Co., Ltd

New P1 trial • Genetic Disorders • Obesity

Assessing Cytochrome P450 Drug Interaction Risk for Dordaviprone Using Physiologically Based Pharmacokinetic Modeling. (PubMed, CPT Pharmacometrics Syst Pharmacol) - "The simulated increase in dordaviprone AUC and Cmax (4.6- and 1.7-fold) following administration of multiple doses of itraconazole was consistent with the observed values (4.4- and 1.9-fold). All PBPK-simulated changes in dordaviprone plasma exposure when administered with CYP3A4 moderate (erythromycin, fluconazole) and weak (cimetidine) inhibitors, and moderate (efavirenz) and strong (rifampicin) inducers were consistent with their CYP3A4 potency classification (AUC ratio = 2.68, 2.48, 1.42, 0.35, and 0.17, respectively). The simulated AUC and Cmax of probe substrates for CYP3A4 (midazolam), CYP2C8 (repaglinide) and CYP2D6 (desipramine) after coadministration with 625 mg dordaviprone were the same as those in the absence of dordaviprone (ratio = 1.0) and remained unchanged after a sensitivity analysis using 10-fold more potent inhibition constants. Due to changes in dordaviprone plasma exposure when co-administered with CYP3A4 inhibitors, dordaviprone dose adjustments..."

Journal • PK/PD data • Brain Cancer • Glioma • Oncology • Solid Tumor

Optimized buccoadhesive repaglinide-loaded cubogel: In-vitro characterization and in-vivo hypoglycemic activity in a streptozotocin-induced diabetic rat model. (PubMed, Int J Pharm X) - "Confocal microscopy further confirmed deep mucosal penetration, while in-vivo studies demonstrated a significant reduction in blood glucose levels compared to the control. Overall, these findings highlight the potential of Opt-RPG-Cubogel as a promising buccoadhesive drug delivery system for efficient type II diabetes management."

Journal • Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Development and Verification of Virtual Population Models for Predicting Drug Pharmacokinetics in Ethnic North American Populations. (PubMed, CPT Pharmacometrics Syst Pharmacol) - "PBPK simulations using the 4 NA population files and repaglinide as a probe compound predicted significant differences in the drug exposure for the Asians, African Americans, and White subjects. In conclusion, the developed population files can aid drug development for specific subgroups of the diverse NA population by accounting for variabilities in drug kinetics and DDI consequences."

Journal • PK/PD data • CYP2C9 • CYP3A4 • CYP3A5

The effects of non-insulin anti-diabetic medications on the diabetic microvascular complications: a systematic review and meta-analysis of randomized clinical trials. (PubMed, BMC Endocr Disord) - "Besides their anti-hyperglycemic properties, some currently reviewed medications may exhibit unique anti-microvascular abilities. Due to ambiguous and conflicting available results, more emerging or ongoing trials will address this issue and could benefit clinical strategies for personalized treatment practices."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Diabetes • Diabetic Nephropathy • Diabetic Neuropathy • Diabetic Retinopathy • Nephrology • Pain • Renal Disease • Retinal Disorders

The Effect of Drug-Drug Interactions on the Pharmacokinetics of Isavuconazole: A Comprehensive Review. (PubMed, Clin Pharmacol) - "The objective of this study was to comprehensive review the impact of drug-drug interactions (DDIs) on isavuconazole pharmacokinetics by categorizing concomitant medications as enzyme inducers (eg, rifampicin), inhibitors (eg, ritonavir), or neutral agents...Rifampicin, flucloxacillin, and phenobarbital decreased the exposure of isavuconazole. Ketoconazole and ritonavir significantly increased the exposure of isavuconazole. Esomeprazole, had no significant effects on the exposure of isavuconazole. Although midazolam, estradiol/norethisterone, atorvastatin, digoxin, metformin, methotrexate, bupropion, repaglinide, dextromethorphan, caffeine, methadone, warfarin, cyclosporine, tacrolimus, sirolimus, prednisone, and mycophenolate mofetil had also no significant effect on isavuconazole pharmacokinetics, a single-dose administration cannot induce or inhibit metabolic enzymes stably, and we consider the results to be unreliable...Single-dose interaction studies are unreliable..."

Journal • PK/PD data • Review • Infectious Disease • Pulmonary Disease • Respiratory Diseases • CYP3A4

Therapeutic potential of repaglinide-embedded chitosan hydrogel in promoting wound healing. (PubMed, Regen Ther) - "The formulation demonstrated enhanced physicochemical and biological properties, including rapid wound closure and improved tissue regeneration. These findings suggest that repaglinide can be repurposed for wound healing applications, particularly for chronic and diabetic wounds, and lay the foundation for future studies on its broader regenerative potential."

Journal • Inflammation

A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open

Emodin, a rising star in the treatment of glycolipid metabolism disorders: a preclinical systematic review and meta-analysis. (PubMed, PeerJ) - "Additionally, emodin shares characteristics with first-line antidiabetic drugs such as metformin, acarbose, and repaglinide, promoting insulin secretion and enhancing cellular sensitivity to insulin. Therefore, emodin is a highly promising drug with substantial research and clinical value. However, caution should be exercised due to significant heterogeneity among the studies, and results may evolve with additional research."

Clinical • Journal • Preclinical • Retrospective data • Review • Diabetes • Dyslipidemia • Metabolic Disorders • Type 2 Diabetes Mellitus